Dare Bioscience announced that safety and tolerability data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female sexual arousal disorder, FSAD, has been published by The Journal of Sexual Medicine. “We were very pleased to see a favorable safety and tolerability profile from both patients and their partners in this study,” said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. “This is a particularly robust safety dataset since it includes assessments of both the participants and their partners.” The exploratory Phase 2b RESPOND study evaluated the systemic and local genital safety of Sildenafil Cream, 3.6%, or Sildenafil Cream, among healthy premenopausal women with FSAD and their sexual partners over a 12-week treatment period. Study data demonstrate that Sildenafil Cream was safe and well tolerated among users and their exposed sexual partners.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Dare Bioscience target adjusted to $13 from $5 at JonesResearch
- Biotech Alert: Searches spiking for these stocks today
- Dare Bioscience downgraded to Hold from Buy at Maxim
- Dare Bioscience announces additional data for Phase 2b RESPOND study
- Dare Bioscience target adjusted to $12 from $6 at H.C. Wainwright
Questions or Comments about the article? Write to editor@tipranks.com